MOUNJARO 15MG PEN ( Tirzepatide 15 mg)

Composition
Each prefilled pen contains Tirzepatide 15 mg as a sterile solution for subcutaneous injection.

Description
MOUNJARO 15 mg Pen is a long-acting injectable antidiabetic medication used for the management of type 2 diabetes mellitus. Tirzepatide acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It improves glycaemic control by enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying and reducing appetite. These combined mechanisms help lower blood glucose levels and support weight reduction when used alongside diet and lifestyle modification.

Adverse Effects
Common adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal pain and reduced appetite, especially during dose escalation. Injection site reactions such as redness, swelling or discomfort may occur. Hypoglycaemia may occur when used in combination with insulin or sulfonylureas.

Precautions
MOUNJARO should be administered only by subcutaneous injection and must not be given intravenously or intramuscularly. Caution is required in patients with a history of pancreatitis, severe gastrointestinal disease or thyroid disorders. Dose escalation should be gradual to minimize gastrointestinal side effects. Use during pregnancy or breastfeeding should be only under medical supervision. Regular monitoring of blood glucose levels is recommended during therapy.

Storage
Store in a refrigerator at 2°C to 8°C and protect from light. Do not freeze. After first use, store as per manufacturer’s instructions. Keep out of reach of children.